新里程(002219) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥744,304,252.04, a decrease of 0.94% compared to the same period last year[4] - The net profit attributable to shareholders was -¥9,963,674.44, representing a significant decline of 697.40% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥18,072,105.28, down 192.72% from the previous year[4] - The basic earnings per share for the period was -¥0.0053, a decrease of 657.14% compared to the same period last year[4] - Net profit for the current period was -¥57,174,950.52, compared to -¥40,997,680.27 in the previous period, indicating a deeper loss[33] - The company reported a basic and diluted earnings per share of -¥0.0317, compared to -¥0.0263 in the previous period[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,985,347,921.82, an increase of 3.41% compared to the end of the previous year[4] - The total liabilities of the company as of September 30, 2021, were approximately CNY 4.29 billion, an increase from CNY 4.09 billion at the end of 2020, representing a rise of about 4.9%[25] - The total liabilities increased to ¥4,884,685,581.14 from ¥4,662,960,688.48, marking a growth of 4.7%[29] - The total equity attributable to shareholders decreased to ¥74,772,530.44, a decline of 44.14% from the previous year-end[4] - The total equity attributable to shareholders of the parent company decreased to ¥74,772,530.44 from ¥133,846,160.94, a decline of 44.0%[29] Cash Flow - The company reported a net cash flow from operating activities of ¥209,549,867.80, which increased by 57.13% year-to-date[4] - Cash flow from operating activities generated ¥2,156,184,193.26, compared to ¥1,993,388,963.26 in the previous period, showing an increase of 8.2%[38] - Operating cash inflow totaled CNY 2,184,543,218.48, an increase of 8.1% from CNY 2,021,131,578.67 in the previous period[41] - Net cash flow from operating activities was CNY 209,549,867.80, compared to CNY 133,361,873.25, representing a 57.1% increase[41] - Cash inflow from financing activities totaled CNY 352,074,000.00, down from CNY 563,590,000.00, a decrease of 37.4%[44] - Net cash flow from financing activities was -CNY 43,062,707.58, an improvement from -CNY 92,354,132.77[44] Expenses - The company's revenue increased, leading to a rise in tax expenses by 36.48% to ¥11,537,065.63[10] - Sales expenses rose by 35.36% to ¥208,258,609.05 due to increased promotional efforts in the pharmaceutical sector[10] - R&D expenditure significantly decreased by 97.64% to ¥38,487.99, indicating reduced investment in research and development[10] - Financial expenses decreased by 40.93% to ¥69,648,211.06, attributed to lower interest expenses from reduced borrowings[10] - Other income surged by 488.38% to ¥12,223,305.67, primarily due to increased government subsidies recognized during the reporting period[10] - The company reported a 40.72% increase in taxes paid, totaling ¥86,387,792.49, reflecting higher revenue[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,071, with no preferred shareholders[11] - The largest shareholder, Que Wenbin, holds 28.93% of the shares, amounting to 539,639,999 shares, which are currently frozen[14] Restructuring and Risks - The company continues to operate during the restructuring process, as approved by the court, allowing ongoing business activities[18] - The company is under a "delisting risk warning" due to the ongoing restructuring process, with its stock still trading under the name "*ST 恒康"[18] - There is a risk of bankruptcy if the restructuring plan is not approved by the court, which could lead to the termination of the company's stock listing[18] - The company has appointed management from Beijing Junhe Law Firm and Gansu Jiezhao Law Firm to oversee the restructuring process[18] Other Financial Metrics - The company experienced a 45.84% increase in prepaid accounts due to unsettled purchases during the reporting period[7] - Cash outflow for the acquisition of fixed assets rose by 45.61% to ¥137,330,673.49, indicating increased capital expenditures[10] - Cash received from loans decreased by 46.73% to ¥220,000,000.00, reflecting a reduction in bank borrowings compared to the previous year[10] - The company's current assets totaled approximately CNY 1.32 billion, up from CNY 1.20 billion at the end of 2020, indicating an increase of around 10.2%[22] - The company's cash and cash equivalents reached approximately CNY 212.92 million, compared to CNY 171.65 million at the end of 2020, reflecting a growth of about 24.1%[22] - The accounts receivable increased to approximately CNY 634.03 million from CNY 568.75 million, marking an increase of about 11.5%[22]